Overview

Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants

Status:
Unknown status
Trial end date:
2015-10-01
Target enrollment:
0
Participant gender:
Female
Summary
We investigate parameters of hemocoagulation and lipoperoxidation in women using combined oral contraceptives with antiandrogenic activity (containing drospirenone with 20 or 30 mcg ethinylestradiol; or cyproterone acetate); correction of these changes by antioxidants
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Tyumen State Medical Academy
Treatments:
Antioxidants
Contraceptive Agents
Contraceptives, Oral
Contraceptives, Oral, Combined
Cyproterone
Cyproterone Acetate
Cyproterone acetate, ethinyl estradiol drug combination
Drospirenone
Drospirenone and ethinyl estradiol combination
Ethinyl Estradiol
Criteria
Inclusion Criteria:

- Women aged 18-35 years

- Absence of contraindications for COC use

- Informed voluntary consent for examination

Exclusion Criteria:

- Age younger than 18 and older than 35 years

- Refusal or failure to comply with the study protocol

- Drug or alcohol dependence

- Psychiatric diseases

- Severe somatic and allergic diseases

- Pregnancy

- Malignancies

- Taking drugs that affect haemostasis, including hormonal contraceptives during 6
months before study beginning

- Cases of thrombosis among first-line relatives in family history

- Contraindications to the COC use under Eligibility Criteria of hormonal contraception
(WHO, 2012)